SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.

被引：0
|
作者：
Bertolini, F
Dell'Agnola, C
Gobbi, A
Monestiroli, S
Pruneri, G
McMahon, G
Martinelli, G
机构：
[1] European Inst Oncl, Milan, Italy
[2] Sugen Inc, San Francisco, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
505
引用
收藏
页码：117A / 117A
页数：1
相关论文
共 50 条
  • [31] Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis
    Cuneo, Kyle C.
    Fu, Allie
    Osusky, Katherine L.
    Geng, Ling
    ANTI-CANCER DRUGS, 2007, 18 (03) : 349 - 355
  • [32] Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells
    Kim, Eun Ho
    Lee, Hanna
    Jeong, Youn Kyoung
    Jung, Won-Gyun
    ONCOLOGY REPORTS, 2016, 36 (02) : 763 - 770
  • [33] Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
    Kentsis, Alex
    Reed, Casie
    Rice, Kim L.
    Sanda, Takaomi
    Rodig, Scott J.
    Tholouli, Eleni
    Christie, Amanda
    Valk, Peter J. M.
    Delwel, Ruud
    Vu Ngo
    Kutok, Jeffery L.
    Dahlberg, Suzanne E.
    Moreau, Lisa A.
    Byers, Richard J.
    Christensen, James G.
    Woude, George Vande
    Licht, Jonathan D.
    Kung, Andrew L.
    Staudt, Louis M.
    Look, A. Thomas
    NATURE MEDICINE, 2012, 18 (07) : 1118 - +
  • [34] Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
    Alex Kentsis
    Casie Reed
    Kim L Rice
    Takaomi Sanda
    Scott J Rodig
    Eleni Tholouli
    Amanda Christie
    Peter J M Valk
    Ruud Delwel
    Vu Ngo
    Jeffery L Kutok
    Suzanne E Dahlberg
    Lisa A Moreau
    Richard J Byers
    James G Christensen
    George Vande Woude
    Jonathan D Licht
    Andrew L Kung
    Louis M Staudt
    A Thomas Look
    Nature Medicine, 2012, 18 : 1118 - 1122
  • [35] PRECLINICAL EVIDENCE THAT TRAMETINIB ENHANCES THE RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA
    Morales, M. L.
    Linares, M.
    Arenas, A.
    Zagorac, I.
    Ayala, R.
    Castro, N.
    Rapado, I.
    Quintela-Fandino, M.
    Martinez-Lopez, J.
    HAEMATOLOGICA, 2017, 102 : 369 - 369
  • [36] PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. IMPROVED OUTCOME IN THE TYROSINE KINASE INHIBITOR ERA
    Dima, M.
    Cucuianu, A.
    Patiu, M.
    Petrov, L.
    Dohner, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 493 - 493
  • [37] Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia
    Martinez-Lopez, Joaquin
    Linares, Maria
    Morales, Maria Luz
    Arenas, Alicia
    Zagorac, Ivana
    Ayala, Rosa M.
    Castro, Nerea
    Rapado, Inmaculada
    Quintela-Fandino, Miguel
    BLOOD, 2016, 128 (22)
  • [38] The angiogenesis inhibitor SU5416 has long lasting effects on VEGF receptor phosphorylation and function.
    Mendel, DB
    Schreck, RE
    West, D
    Li, G
    Strawn, LS
    Tanciangco, SS
    Shawver, LK
    Cherrington, JM
    CLINICAL CANCER RESEARCH, 2000, 6 : 4582S - 4582S
  • [39] The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine
    Kelly, Kevin R.
    Swords, Ronan T.
    Mahalingam, Devalingam
    Nawrocki, Steffan T.
    Medina, Ernest
    Smith, Sabrina
    Padmanabhan, Swaminathan
    Ecsedy, Jeffrey
    Cahill, Mary R.
    Giles, Francis J.
    Carew, Jennifer S.
    BLOOD, 2009, 114 (22) : 824 - 824
  • [40] Tyrosine kinase inhibition in acute myeloid leukemia
    Altman, Jessica K.
    Szilard, Amy K.
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1351 - 1352
12345